Operational Setbacks and Regulatory Headwinds Justify Maintaining Hold on Integra

BTIG analyst Ryan Zimmerman has maintained their neutral stance on IART stock, giving a Hold rating on February 3.

Ryan Zimmerman has given his Hold rating due to a combination of factors tied to Integra’s ongoing operational and product challenges. The company has spent years overhauling its quality systems, manufacturing footprint, and leadership, yet new issues keep emerging, such as the recent scrutiny of the TruDi Navigation System following FDA incident reports highlighted in a Reuters investigation.

Zimmerman also points to the MediHoney line remaining off the market after an FDA alert on sterile packaging, which is likely to weigh on revenue for several quarters. While the Acclarent acquisition was intended to enhance growth and synergies, performance in ENT and navigation has been uneven, and visibility into a sustained turnaround remains limited. As a result, although the stock already trades at a discounted level that tempers downside risk, he does not yet see sufficient evidence of improved execution to justify a more positive rating.

Zimmerman covers the Healthcare sector, focusing on stocks such as Organogenesis Holdings, GE Healthcare Technologies Inc, and Solventum Corporation. According to TipRanks, Zimmerman has an average return of -0.6% and a 40.80% success rate on recommended stocks.

In another report released on February 3, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $11.00 price target.